Abstract
Objective: To investigate the effect of cucurmosin (CUS) on proliferation inhibition in the human pancreatic cancer cell line SW-1990 in vitro and in vivo.
Methods: 1. MTT assay was used to analyse the proliferation inhibition of CUS in SW-1990 cells compared with gemcitabine (GEM) in vitro. 2. We established an NOD-SCID mice orthotopic transplantation model and estimated the proliferation inhibition effect of CUS in SW-1990 cells in vivo. 3. Western blot was used to determine the protein expressions of Caspase 3, Bcl-2, Caspase 9, PI3K, Akt, mTOR, P70S6k, and 4E-BP1 after CUS intervention.
Results: 1. CUS inhibited the proliferation of pancreatic cancer cells and induced apoptosis in CUS dose- and time-dependent manners. 2. NOD-SCID mice models were established successfully, and the tumour proliferation inhibition rates of these models increased compared with the control group. 3. CUS inhibited all of the examined proteins in the PI3K/Akt/mTOR signalling pathway and induced active fragments of Caspase 3 and Caspase 9.
Conclusion: 1. CUS can inhibit the growth of SW-1990 cells in vitro and in vivo. 2. CUS can induce apoptosis in SW-1990 cells to inhibit cell growth.
Keywords: Pancreatic cancer, cucurmosin, proliferation inhibition, apoptosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Cucurmosin Kills Human Pancreatic Cancer SW-1990 Cells in vitro and in vivo
Volume: 13 Issue: 6
Author(s): Jieming Xie, Congfei Wang, Aiqin Yang, Baoming Zhang, Qiang Yin, Heguang Huang and Minghuang Chen
Affiliation:
Keywords: Pancreatic cancer, cucurmosin, proliferation inhibition, apoptosis.
Abstract: Objective: To investigate the effect of cucurmosin (CUS) on proliferation inhibition in the human pancreatic cancer cell line SW-1990 in vitro and in vivo.
Methods: 1. MTT assay was used to analyse the proliferation inhibition of CUS in SW-1990 cells compared with gemcitabine (GEM) in vitro. 2. We established an NOD-SCID mice orthotopic transplantation model and estimated the proliferation inhibition effect of CUS in SW-1990 cells in vivo. 3. Western blot was used to determine the protein expressions of Caspase 3, Bcl-2, Caspase 9, PI3K, Akt, mTOR, P70S6k, and 4E-BP1 after CUS intervention.
Results: 1. CUS inhibited the proliferation of pancreatic cancer cells and induced apoptosis in CUS dose- and time-dependent manners. 2. NOD-SCID mice models were established successfully, and the tumour proliferation inhibition rates of these models increased compared with the control group. 3. CUS inhibited all of the examined proteins in the PI3K/Akt/mTOR signalling pathway and induced active fragments of Caspase 3 and Caspase 9.
Conclusion: 1. CUS can inhibit the growth of SW-1990 cells in vitro and in vivo. 2. CUS can induce apoptosis in SW-1990 cells to inhibit cell growth.
Export Options
About this article
Cite this article as:
Xie Jieming, Wang Congfei, Yang Aiqin, Zhang Baoming, Yin Qiang, Huang Heguang and Chen Minghuang, Cucurmosin Kills Human Pancreatic Cancer SW-1990 Cells in vitro and in vivo, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990109
DOI https://dx.doi.org/10.2174/18715206113139990109 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Current Radiopharmaceuticals Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics Sperm Chromatin Protamination: An Endocrine Perspective
Protein & Peptide Letters Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Pluripotency-Regulating Networks Provide Basis for Reprogramming
Current Molecular Medicine Editorial (Thematic Issue: Elderly Cancer Patients in the 3rd Millenium: Between Hope and Reality. Introduction)
Anti-Cancer Agents in Medicinal Chemistry Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Obesity in China: What are the Causes?
Current Pharmaceutical Design Medical Therapy and Mucosal Healing
Current Drug Targets Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Membrane-Targeted Self-Assembling Cyclic Peptide Nanotubes
Current Topics in Medicinal Chemistry Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)